Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 19, 2026, 8:02 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 266 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Oral Cavity Infection Clear all
Completed Phase 1 Interventional

Comparison of Two Dosage Regimens of Oral Dapsone for Prophylaxis of Pneumocystis Carinii Pneumonia in Pediatric HIV Infection

NCT00000739
View directory record Official record
Conditions
Pneumonia, Pneumocystis Carinii, HIV Infections
Interventions
Dapsone
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
1 Month to 12 Years
Enrollment
96 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 1998
U.S. locations
43
States / cities
Long Beach, California • Los Angeles, California • Oakland, California + 29 more
Source: ClinicalTrials.gov public record
Updated Nov 3, 2021 · Synced Sep 19, 2026, 8:02 AM EDT
Completed Phase 1 Interventional

Combination Chemotherapy Plus Filgrastim in Treating Patients With Advanced Solid Tumors

NCT00014456
View directory record Official record
Conditions
Bladder Cancer, Breast Cancer, Carcinoma of Unknown Primary, Esophageal Cancer, Gastric Cancer, Head and Neck Cancer, Lung Cancer, Melanoma (Skin), Ovarian Cancer, Pancreatic Cancer, Prostate Cancer, Sarcoma
Interventions
filgrastim, docetaxel, gemcitabine hydrochloride
Biological · Drug
Lead sponsor
Dartmouth-Hitchcock Medical Center
Other
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2005
U.S. locations
1
States / cities
Lebanon, New Hampshire
Source: ClinicalTrials.gov public record
Updated Aug 27, 2013 · Synced Sep 19, 2026, 8:02 AM EDT
Completed Phase 2 Interventional

Pilot Study of the Safety and Clinical Efficacy of Topical Dermacyn™ Wound Care to Treat Mild Diabetic Foot Infections

NCT00516958
View directory record Official record
Conditions
Foot Ulcer, Diabetic
Interventions
Topical Dermacyn, Topical Dermacyn and Levofloxacin, Topical Saline and Levofloxacin
Drug
Lead sponsor
Oculus Innovative Sciences, Inc.
Industry
Eligibility
18 Years and older
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007
U.S. locations
16
States / cities
Tucson, Arizona • La Jolla, California • Los Angeles, California + 13 more
Source: ClinicalTrials.gov public record
Updated Jan 13, 2008 · Synced Sep 19, 2026, 8:02 AM EDT
Terminated Phase 4 Interventional

Oral Vancomycin for Preventing Clostridium Difficile Recurrence

NCT03200093
View directory record Official record
Conditions
Clostridium Difficile Infection
Interventions
Oral Vancomycin, Placebo
Drug
Lead sponsor
Rochester General Hospital
Other
Eligibility
18 Years and older
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Apr 25, 2021 · Synced Sep 19, 2026, 8:02 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers

Spirulina Oral Supplement for Enhancing Host Resilience to Virus Infection

NCT05447078
View directory record Official record
Conditions
Healthy Volunteers
Interventions
Immulina TM, Placebo
Drug · Dietary Supplement
Lead sponsor
University of Mississippi Medical Center
Other
Eligibility
18 Years and older
Enrollment
492 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2025
U.S. locations
1
States / cities
Jackson, Mississippi
Source: ClinicalTrials.gov public record
Updated Jul 29, 2026 · Synced Sep 19, 2026, 8:02 AM EDT
Completed Phase 3 Interventional

Measurement of Viral Load Reduction in the Oral Cavity After a Regimental Use of OC Toothpaste Products

NCT04864925
View directory record Official record
Conditions
Covid19
Interventions
Colgate Total Clean Mint, Tom's Botanically Bright Peppermint
Drug
Lead sponsor
Colgate Palmolive
Industry
Eligibility
18 Years to 64 Years
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Newark, New Jersey
Source: ClinicalTrials.gov public record
Updated Jan 17, 2022 · Synced Sep 19, 2026, 8:02 AM EDT
Not listed Phase 3 Interventional Accepts healthy volunteers

A Phase 3 Randomized Double Blind Efficacy and Safety Study of Oral Polio Vaccine and NA-831 for Covid-19

NCT04540185
View directory record Official record
Conditions
Covid19, SARS (Severe Acute Respiratory Syndrome), SARS-CoV Infection, SARS-CoV-2
Interventions
Biological: oral polio vaccine, Comparable Placebo, NA-831, Comparable Placebo of drug, Combination of oral polio vaccine and NA-831, Comparable Placebo of Oral Polio Vaccine and Placebo of drug
Biological · Drug · Combination Product
Lead sponsor
Biomed Industries, Inc.
Industry
Eligibility
18 Years and older
Enrollment
3,600 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2022
U.S. locations
8
States / cities
Los Angeles, California • Orange, California • Palo Alto, California + 4 more
Source: ClinicalTrials.gov public record
Updated Sep 8, 2020 · Synced Sep 19, 2026, 8:02 AM EDT
Completed Not applicable Interventional

A Systematic Oral Care Program in Post-Mechanically Ventilated, Post-Intensive Care Patients

NCT03886623
View directory record Official record
Conditions
Methicillin-resistant Staphylococcus Aureus, Methicillin-Sensitive Staphylococcus Aureus Infection
Interventions
4-day systematic oral hygiene, Standard of Care oral care
Procedure · Other
Lead sponsor
Ohio State University
Other
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Mar 21, 2019 · Synced Sep 19, 2026, 8:02 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Oral H. Pylori Prevalence in Intellectually & Developmentally Disabled Adults

NCT00841490
View directory record Official record
Conditions
Helicobacter Pylori Infection
Interventions
Not listed
Lead sponsor
University of Louisville
Other
Eligibility
18 Years to 90 Years
Enrollment
220 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2012
U.S. locations
2
States / cities
Louisville, Kentucky • Somerset, Kentucky
Source: ClinicalTrials.gov public record
Updated Apr 13, 2017 · Synced Sep 19, 2026, 8:02 AM EDT
Completed Phase 1Phase 2 Interventional

Valganciclovir in Congenital CMV Infants

NCT00031434
View directory record Official record
Conditions
Cytomegalovirus Infections
Interventions
Valganciclovir, Ganciclovir
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
Up to 30 Days
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2007
U.S. locations
21
States / cities
Birmingham, Alabama • Little Rock, Arkansas • Los Angeles, California + 18 more
Source: ClinicalTrials.gov public record
Updated Feb 6, 2011 · Synced Sep 19, 2026, 8:02 AM EDT
Completed Phase 2 Interventional Results available

Open-Label Extension of CP101 Trials Evaluating Oral Full-Spectrum Microbiota™ (CP101) in Subjects With Recurrence of Clostridium Difficile Infection

NCT03497806
View directory record Official record
Conditions
Clostridium Difficile Infection, Recurrent Clostridium Difficile Infection, C. Diff, CDI, Recurrent C. Diff, rCDI, C. Difficile, Recurrent CDI, FMT, Fecal Microbiota, Fecal Transplant
Interventions
CP101
Biological
Lead sponsor
Finch Research and Development LLC.
Industry
Eligibility
18 Years and older
Enrollment
132 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
53
States / cities
Scottsdale, Arizona • Los Angeles, California • Murrieta, California + 47 more
Source: ClinicalTrials.gov public record
Updated Aug 29, 2022 · Synced Sep 19, 2026, 8:02 AM EDT
Completed Phase 2 Interventional Results available

Efficacy, Safety, and Tolerability Study of Oral Full-Spectrum MicrobiotaTM (CP101) in Subjects With Recurrent C. Diff

NCT03110133
View directory record Official record
Conditions
Clostridium Difficile Infection Recurrence
Interventions
Full Spectrum Microbiota, Placebo
Drug
Lead sponsor
Finch Research and Development LLC.
Industry
Eligibility
18 Years and older
Enrollment
206 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
54
States / cities
Scottsdale, Arizona • Los Angeles, California • Murrieta, California + 48 more
Source: ClinicalTrials.gov public record
Updated Oct 4, 2022 · Synced Sep 19, 2026, 8:02 AM EDT
Not listed Phase 1Phase 2 Interventional

Study of Talactoferrin Oral Solution for Nosocomial Infection in Preterm Infants

NCT00854633
View directory record Official record
Conditions
Nosocomial Infections
Interventions
Talactoferrin, Placebo
Drug
Lead sponsor
Agennix
Industry
Eligibility
1 Minute to 24 Hours
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
4
States / cities
Los Angeles, California • Louisville, Kentucky • Columbia, Missouri
Source: ClinicalTrials.gov public record
Updated Mar 14, 2012 · Synced Sep 19, 2026, 8:02 AM EDT
Completed Not applicable Interventional

Randomized Trial to Assess PO Versus IV Antibiotics

NCT01714596
View directory record Official record
Conditions
Wound Infection
Interventions
PO versus IV antibiotics Route of administration evaluation
Other
Lead sponsor
Major Extremity Trauma Research Consortium
Other
Eligibility
18 Years to 84 Years
Enrollment
233 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2020
U.S. locations
24
States / cities
Birmingham, Alabama • Los Angeles, California • San Francisco, California + 21 more
Source: ClinicalTrials.gov public record
Updated Feb 10, 2021 · Synced Sep 19, 2026, 8:02 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Single Dose Study of Debio 1450 in Healthy Subjects

NCT02162199
View directory record Official record
Conditions
Bacterial Infections
Interventions
Debio 1450, Placebo
Drug
Lead sponsor
Debiopharm International SA
Industry
Eligibility
18 Years to 55 Years
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 22, 2014 · Synced Sep 19, 2026, 8:02 AM EDT
Completed Phase 2 Interventional Results available

Strategies To Prevent Pneumonia 2 (SToPP2)

NCT00893763
View directory record Official record
Conditions
Infections, Hospital, Ventilator-Associated Pneumonia, Mechanical Ventilation Complication
Interventions
Pre-intubation CHX, Control
Procedure
Lead sponsor
University of South Florida
Other
Eligibility
18 Years and older
Enrollment
314 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
1
States / cities
Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Jan 10, 2016 · Synced Sep 19, 2026, 8:02 AM EDT
Completed Phase 2 Interventional

High-dose ICE With Amifostine

NCT00003657
View directory record Official record
Conditions
Bladder Cancer, Brain and Central Nervous System Tumors, Carcinoma of Unknown Primary, Extragonadal Germ Cell Tumor, Head and Neck Cancer, Kidney Cancer, Lung Cancer, Ovarian Cancer, Sarcoma, Testicular Germ Cell Tumor, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
filgrastim, Amifostine, Carboplatin, Etoposide, Ifosfamide, peripheral blood stem cell transplantation
Biological · Drug · Procedure
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years to 55 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2002
U.S. locations
3
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 19, 2017 · Synced Sep 19, 2026, 8:02 AM EDT
Completed Phase 2 Interventional Results available

Evaluation of Activity and Safety of Oral Selinexor in Participants With Severe COVID-19 Infection

NCT04349098
View directory record Official record
Conditions
Coronavirus Infection
Interventions
Selinexor, Placebo
Drug · Other
Lead sponsor
Karyopharm Therapeutics Inc
Industry
Eligibility
18 Years and older
Enrollment
190 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
20
States / cities
Los Angeles, California • Oakland, California • Sacramento, California + 15 more
Source: ClinicalTrials.gov public record
Updated Jan 19, 2023 · Synced Sep 19, 2026, 8:02 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety and Efficacy Study of CVD 1208S, a Live, Attenuated Oral Vaccine to Prevent Shigella Infection Using cGMP

NCT01531530
View directory record Official record
Conditions
Shigella
Interventions
CVD 1208S, a Shigella flexneri 2a live, oral vaccine, Placebo
Biological · Other
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years to 45 Years
Enrollment
26 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2012
U.S. locations
2
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 29, 2021 · Synced Sep 19, 2026, 8:02 AM EDT
Completed Phase 1 Interventional

MS-275 in Treating Patients With Advanced Solid Tumors or Lymphoma

NCT00020579
View directory record Official record
Conditions
Cancer
Interventions
entinostat
Drug
Lead sponsor
National Institutes of Health Clinical Center (CC)
NIH
Eligibility
18 Years and older
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2008
U.S. locations
3
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 14, 2012 · Synced Sep 19, 2026, 8:02 AM EDT
Completed Not applicable Interventional

Study of Prophylactic Vs Preemptive Valganciclovir

NCT00374686
View directory record Official record
Conditions
Cytomegalovirus Infection
Interventions
Valganciclovir
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years to 85 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2005
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Sep 10, 2006 · Synced Sep 19, 2026, 8:02 AM EDT
Withdrawn Not applicable Interventional

The Effect of Oral Antibiotics on Synovial Fluid and Differential for the Diagnosis of Infection

NCT03551847
View directory record Official record
Conditions
Infection
Interventions
Antibiotic, No antibiotics
Drug
Lead sponsor
Rush University Medical Center
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2019
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Aug 22, 2021 · Synced Sep 19, 2026, 8:02 AM EDT
Completed Phase 2 Interventional Results available

Evaluation of CRS3123 vs. Oral Vancomycin in Adult Patients With Clostridioides Difficile Infection

NCT04781387
View directory record Official record
Conditions
Clostridioides Difficile Infection
Interventions
CRS3123, Active Comparator
Drug
Lead sponsor
Crestone, Inc
Industry
Eligibility
18 Years and older
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
18
States / cities
Fullerton, California • Lancaster, California • Mission Hills, California + 14 more
Source: ClinicalTrials.gov public record
Updated Mar 26, 2026 · Synced Sep 19, 2026, 8:02 AM EDT
Completed No phase listed Observational

Topical Antisepsis in Head and Neck Cancer Surgery

NCT04721626
View directory record Official record
Conditions
Head and Neck Cancer
Interventions
Chlorhexidine Gluconate, Povidone-iodine, Tetracycline Ointment
Drug
Lead sponsor
Medical College of Wisconsin
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Feb 6, 2022 · Synced Sep 19, 2026, 8:02 AM EDT